CARLSBAD, Calif. & HAYWARD, Calif. & CAMBRIDGE, United Kingdom–Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, and Solexa, Inc. (Nasdaq:SLXA), a provider of next-generation genetic analysis systems, announced a collaboration through which Invitrogen will supply many of the reagents for Solexa’s sequencing, gene expression, and small RNA analysis kits designed to be used with the Solexa Genome Analysis System. Financial terms of the collaboration were not disclosed.
With the potential to generate over a billion bases of DNA sequence data per run, Solexa expects the Solexa Genome Analysis System to reduce the cost and improve the speed of a broad range of applications, including whole genome human sequencing and expression profiling. Solexa’s platform, which leverages the company’s proprietary Clonal Single Molecule Array(TM) technology and reversible-terminator chemistry, has the versatility and scalability to address researchers’ needs in a range of settings, including core facilities, genome centers, and individual laboratories. Solexa is currently taking orders for the system and expects to commence broad shipment of the technology platform in fall 2006.